- Home
- EDF vs PLX Comparison
EDF vs PLX Comparison
Compare EDF & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- PLX
- Stock Information
- Founded
- EDF 2010
- PLX 1993
- Country
- EDF United States
- PLX United States
- Employees
- EDF N/A
- PLX N/A
- Industry
- EDF Investment Managers
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDF Finance
- PLX Health Care
- Exchange
- EDF Nasdaq
- PLX Nasdaq
- Market Cap
- EDF 148.8M
- PLX 160.2M
- IPO Year
- EDF N/A
- PLX 1998
- Fundamental
- Price
- EDF $4.94
- PLX $1.55
- Analyst Decision
- EDF
- PLX Strong Buy
- Analyst Count
- EDF 0
- PLX 1
- Target Price
- EDF N/A
- PLX $15.00
- AVG Volume (30 Days)
- EDF 160.6K
- PLX 1.4M
- Earning Date
- EDF 01-01-0001
- PLX 05-09-2025
- Dividend Yield
- EDF 13.14%
- PLX N/A
- EPS Growth
- EDF N/A
- PLX N/A
- EPS
- EDF N/A
- PLX 0.05
- Revenue
- EDF N/A
- PLX $59,764,000.00
- Revenue This Year
- EDF N/A
- PLX $65.02
- Revenue Next Year
- EDF N/A
- PLX $57.34
- P/E Ratio
- EDF N/A
- PLX $32.18
- Revenue Growth
- EDF N/A
- PLX 0.18
- 52 Week Low
- EDF $3.51
- PLX $0.82
- 52 Week High
- EDF $5.50
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- EDF 54.12
- PLX 30.03
- Support Level
- EDF $4.90
- PLX $1.54
- Resistance Level
- EDF $5.03
- PLX $1.79
- Average True Range (ATR)
- EDF 0.07
- PLX 0.11
- MACD
- EDF 0.00
- PLX -0.02
- Stochastic Oscillator
- EDF 50.00
- PLX 27.27
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.